Eli Lilly launches higher doses of Zepbound, lowers price of certain vials
People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...
Construction Dive13h
Eli Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Opinion
Zacks.com on MSN14hOpinion
Top Research Reports for Amazon, Eli Lilly & S&P Global
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly ...
Eli Lilly wants to make drugs in America. First it wants a tax cut
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 ...
Lock Haven4h
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...
Promising Medical Stocks To Add to Your Watchlist – February 26th
Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...
Managed Healthcare Executive18h
MedImpact Adds the Biosimilars Selarsdi and Yesintek to Formulary
Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of ...